Conventional immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) elicit durable survival but primarily in patients with immune-inflamed tumors. Although the mechanisms underlying response to anti–CTLA-4 remain poorly understood, Fc-gamma receptor (FcγR) IIIA coengagement seems critical for activity, potentially explaining the modest clinical benefits of approved anti–CTLA-4 antibodies. We demonstrate that anti–CTLA-4 engineered for enhanced FcγR affinity leverages FcγR-dependent mechanisms to potentiate T-cell responsiveness, reduce intratumoral regulatory T cells, and enhance antigen-presenting cell activation. Fc-enhanced anti–CTLA-4 promoted superior efficacy in mouse models and remodeled innate and adaptive immunity versus conventional anti–CTLA-4. These findings extend to patients treated with botensilimab, an Fc-enhanced anti–CTLA-4 antibody, with clinical activity across multiple poorly immunogenic and ICI treatment–refractory cancers. Efficacy was independent of tumor neoantigen burden or FCGR3A genotype. However, FCGR2A and FCGR3A expression emerged as potential response biomarkers. These data highlight the therapeutic potential of Fc-enhanced anti–CTLA-4 antibodies in cancers unresponsive to conventional ICI therapy. Significance: This study reveals that Fc-enhanced anti–CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti–CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a new class of immuno-oncology agents, capable of extending clinical benefit to patients with cancers resistant to current immunotherapies.
In recent years, there has been considerable interest in mAb-based induction of costimulatory receptor signaling as an approach to combat cancer. However, promising nonclinical data have yet to translate to a meaningful clinical benefit. Inducible T-cell costimulator (ICOS) is a costimulatory receptor important for immune responses. Using a novel clinical-stage anti-ICOS immunoglobulin G4 mAb (feladilimab), which induces but does not deplete ICOS+ T cells and their rodent analogs, we provide an end-to-end evaluation of the antitumor potential of antibody-mediated ICOS costimulation alone and in combination with programmed cell death protein 1 (PD-1) blockade. We demonstrate, consistently, that ICOS is expressed in a range of cancers, and its induction can stimulate growth of antitumor reactive T cells. Furthermore, feladilimab, alone and with a PD-1 inhibitor, induced antitumor activity in mouse and humanized tumor models. In addition to nonclinical evaluation, we present three patient case studies from a first-time-in-human, phase I, open-label, dose-escalation and dose-expansion clinical trial (INDUCE-1; ClinicalTrials.gov: NCT02723955), evaluating feladilimab alone and in combination with pembrolizumab in patients with advanced solid tumors. Preliminary data showing clinical benefit in patients with cancer treated with feladilimab alone or in combination with pembrolizumab was reported previously; with example cases described here. Additional work is needed to further validate the translation to the clinic, which includes identifying select patient populations that will benefit from this therapeutic approach, and randomized data with survival endpoints to illustrate its potential, similar to that shown with CTLA-4 and PD-1 blocking antibodies. Significance: Stimulation of the T-cell activation marker ICOS with the anti-ICOS agonist mAb feladilimab, alone and in combination with PD-1 inhibition, induces antitumor activity across nonclinical models as well as select patients with advanced solid tumors.
This table presents a comparison of the binding epitopes of botensilimab, ipilimumab, and tremelimumab on human CTLA-4. It highlights the specific amino acid residues on CTLA-4 that are involved in the binding interface for each antibody. This comparison provides insight into binding characteristics of botensilimab relative to established anti-CTLA-4 therapies.
This dataset presents the pharmacokinetic (PK) profile of mouse Fc-enhanced anti-CTLA-4 antibody versus the parental anti-CTLA-4 antibody. The PK profile is important for interpreting the efficacy data, and further supports the conclusion that the enhanced anti-tumor effects are likely due to the engineered Fc-mediated functions rather than altered drug exposure or persistence in the body.
This dataset shows that response to botensilimab, alone or with balstilimab, in patients with advanced cancers is independent of tumor neoantigen burden and FcγRIIIA allele status. This suggests that botensilimab's efficacy may be broad and not limited by these commonly used biomarkers typically associated with response to conventional immune checkpoint therapy. The data highlights a potential advantage of botensilimab over traditional immunotherapies, indicating it might be effective in a wider range of patients, including those who may not typically respond to standard checkpoint inhibitors.
This dataset provides detailed information on the binding characteristics and functional properties of botensilimab. This comprehensive dataset demonstrates botensilimab's high affinity and selectivity for CTLA-4, its ability to effectively block CTLA-4 interactions with its ligands comparable to that of the parental IgG1 anti-CTLA-4 antibody. Importantly, this data further supports that the superior functional attributes of botensilimab are due to the Fc-engineered region and not the variable region of the antibody.